Patents by Inventor Patrick Stahl

Patrick Stahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
    Publication number: 20220265596
    Abstract: The present invention is directed to pharmaceutical formulations of therapeutic proteins that comprise one or more polyethoxylated fatty alcohol (PFA) surfactants that are resistant to lipase mediated degradation. The present invention is also directed to methods of reducing aggregate and/or particulate formation in pharmaceutical formulations of therapeutic proteins and methods of maintaining a stable surfactant level in pharmaceutical formulations of therapeutic proteins.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Inventors: Steven LaBrenz, Patrick Stahl
  • Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody
    Publication number: 20220064307
    Abstract: Provided herein are stable aqueous pharmaceutical compositions comprising formulations of a bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and methods of preparing the same. Also provided herein are methods of treating cancer in a subject in need thereof by administering to the subject the stable aqueous pharmaceutical compositions as disclosed herein. Further provided herein are kits and articles of manufacture comprising the stable aqueous pharmaceutical compositions as disclosed herein.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Jessica Kupec, Melissa Schreyer, Patrick Stahl, Satyen Torne
  • Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
    Publication number: 20200061015
    Abstract: The present invention is directed to pharmaceutical formulations of therapeutic proteins that comprise one or more polyethoxylated fatty alcohol (PFA) surfactants that are resistant to lipase mediated degradation. The present invention is also directed to methods of reducing aggregate and/or particulate formation in pharmaceutical formulations of therapeutic proteins and methods of maintaining a stable surfactant level in pharmaceutical formulations of therapeutic proteins.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 27, 2020
    Inventors: Steven LaBrenz, Patrick Stahl